FDA approves Regeneron's Livsayin (cemdisiran) for AChR‑positive generalized myasthenia gravis
Regeneron Pharmaceuticals received FDA approval on November 18, 2026 for Livsayin (cemdisiran), the first siRNA therapy for generalized myasthenia gravis (gMG) in adults with anti‑acetylcholine‑receptor antibodies. The drug is administered subcutaneously four times a year and showed a 4.5‑point improvement on the MG‑ADL scale versus 2.2 points for placebo, a 2.3‑point placebo‑adjusted difference, and 76.6% of patients were responders compared with 44.1% on placebo. Regeneron licensed the product from Alnylam, and the label carries a boxed warning for serious meningococcal infections.
Why it matters
The approval adds Regeneron's first neurology product and its first siRNA therapy, expanding its pipeline and potential revenue stream. The company disclosed a list price of $410,000 per year, indicating a high‑margin specialty drug opportunity for investors. Alnylam benefits from licensing royalties on the new product.
Key facts
- 1The FDA approved Livsayin on November 18, 2026. ajmc.com
- 2Livsayin is the first and only approved siRNA therapy for generalized myasthenia gravis. ajmc.com
- 3The drug is given subcutaneously four times a year. quantisnow.com
- 4In the phase‑3 NIMBLE trial, MG‑ADL scores improved 4.5 points versus 2.2 points with placebo, a placebo‑adjusted difference of 2.3 points. ajmc.com
- 576.6% of patients on Livsayin were MG‑ADL responders versus 44.1% on placebo. quantisnow.com
- 6Regeneron disclosed a list price of $410,000 annually. finance.yahoo.com
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.